X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2486) 2486
Book Review (423) 423
Publication (323) 323
Conference Proceeding (12) 12
Book Chapter (6) 6
Magazine Article (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2309) 2309
humans (2191) 2191
bortezomib (2171) 2171
boronic acids - administration & dosage (1285) 1285
pyrazines - administration & dosage (1239) 1239
male (1098) 1098
female (1035) 1035
multiple myeloma - drug therapy (998) 998
oncology (984) 984
middle aged (870) 870
aged (794) 794
antineoplastic combined chemotherapy protocols - therapeutic use (788) 788
boronic acids - therapeutic use (748) 748
hematology (747) 747
pyrazines - therapeutic use (722) 722
multiple myeloma (682) 682
boronic acids - pharmacology (601) 601
animals (577) 577
adult (564) 564
treatment outcome (544) 544
pyrazines - pharmacology (528) 528
boronic acids - adverse effects (515) 515
pyrazines - adverse effects (504) 504
antineoplastic agents - therapeutic use (481) 481
dexamethasone - administration & dosage (444) 444
cancer (412) 412
apoptosis (357) 357
thalidomide - administration & dosage (350) 350
mice (348) 348
antineoplastic agents - administration & dosage (333) 333
cell line, tumor (330) 330
proteasome inhibitors (325) 325
multiple-myeloma (320) 320
therapy (315) 315
antineoplastic agents - pharmacology (311) 311
chemotherapy (310) 310
thalidomide - analogs & derivatives (292) 292
aged, 80 and over (288) 288
apoptosis - drug effects (286) 286
dexamethasone (284) 284
antineoplastic combined chemotherapy protocols - adverse effects (283) 283
care and treatment (264) 264
multiple myeloma - pathology (262) 262
thalidomide (257) 257
antineoplastic agents - adverse effects (253) 253
stem-cell transplantation (246) 246
nf-kappa-b (220) 220
dose-response relationship, drug (219) 219
research (217) 217
recurrence (207) 207
protease inhibitors - therapeutic use (206) 206
drug therapy (200) 200
article (198) 198
pharmacology & pharmacy (198) 198
transplantation (198) 198
antineoplastic combined chemotherapy protocols - administration & dosage (195) 195
hematology, oncology and palliative medicine (193) 193
drug administration schedule (191) 191
multiple myeloma - mortality (190) 190
multiple myeloma - therapy (187) 187
proteasome inhibitor bortezomib (185) 185
trial (182) 182
medicine & public health (180) 180
analysis (178) 178
thalidomide - therapeutic use (176) 176
abridged index medicus (172) 172
melphalan - administration & dosage (171) 171
disease-free survival (170) 170
survival (170) 170
multiple myeloma - complications (169) 169
drug synergism (168) 168
prognosis (168) 168
doxorubicin - administration & dosage (167) 167
dosage and administration (163) 163
retrospective studies (163) 163
lenalidomide (162) 162
boronic acids - chemistry (158) 158
protease inhibitors - pharmacology (157) 157
proteasome inhibitor (157) 157
remission induction (156) 156
combination (155) 155
proteasome endopeptidase complex - metabolism (151) 151
health aspects (150) 150
transplantation, autologous (145) 145
cells (144) 144
cell proliferation - drug effects (143) 143
proteasome (141) 141
clinical trials as topic (135) 135
follow-up studies (131) 131
drug resistance, neoplasm (130) 130
hemic and lymphatic diseases (130) 130
expression (128) 128
activation (127) 127
cyclophosphamide - administration & dosage (127) 127
melphalan (124) 124
protease inhibitors - administration & dosage (124) 124
proteasome inhibitor ps-341 (124) 124
refractory myeloma (124) 124
survival analysis (123) 123
combined modality therapy (122) 122
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2329) 2329
Japanese (52) 52
Chinese (50) 50
French (21) 21
Czech (9) 9
Russian (8) 8
German (7) 7
Hungarian (5) 5
Spanish (5) 5
Polish (4) 4
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 10/2013, Volume 135, Issue 41, pp. 15501 - 15507
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2012, Volume 30, Issue 24, pp. 2946 - 2955
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 07/2015, Volume 74, Issue 7, pp. 1474 - 1478
ObjectivesTo investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC)... 
CARFILZOMIB | THERAPY | DOSE DEXAMETHASONE | MEMORY | REJECTION | DISEASE | NEPHRITIS | RELAPSED MULTIPLE-MYELOMA | MICE | RHEUMATOLOGY | Humans | Pyrazines - administration & dosage | Lupus Erythematosus, Systemic - metabolism | Male | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Plasma Cells - pathology | Plasma Cells - drug effects | Lupus Erythematosus, Systemic - drug therapy | Lupus Erythematosus, Systemic - immunology | Interferon Type I - metabolism | Adult | Female | Boronic Acids - administration & dosage | Drug Therapy, Combination | Severity of Illness Index | Bortezomib | Dexamethasone - administration & dosage | DNA - immunology | Proteasome Inhibitors - pharmacology | Proteasome Inhibitors - administration & dosage | Treatment Outcome | Proteasome Inhibitors - therapeutic use | Administration, Intravenous | Dexamethasone - therapeutic use | Antibodies - blood | Pyrazines - pharmacology | Germany | Boronic Acids - pharmacology | Complications and side effects | Treatment outcome | Systemic lupus erythematosus | Analysis | Multiple myeloma | Dosage and administration | Drug therapy | Risk factors | Lupus | Studies | Immunoglobulins | Protease inhibitors | Disease | Bone marrow | Vaccines | Index Medicus | Systemic Lupus Erythematosus | Autoimmunity | Treatment | Autoimmune Diseases | Basic and Translational Research | B cells | 1506
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article